Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence  in situ  hybridization (FISH) to select the optimal patients for matched therapy?

Young Kwang Chae; Ayush Arya; Lauren Chiec; Hiral Shah; Ari Rosenberg; Sandip Patel; Kirtee Raparia; Jaehyuk Choi; Derek A. Wainwright; Victoria Villaflor; Massimo Cristofanilli; Francis Giles

doi:10.18632/oncotarget.19809

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Young Kwang Chae _, Ayush Arya, Lauren Chiec, Hiral Shah, Ari Rosenberg, Sandip Patel, Kirtee Raparia, Jaehyuk Choi, Derek A. Wainwright, Victoria Villaflor, Massimo Cristofanilli and Francis Giles

PDF | HTML | How to cite

Oncotarget. 2017; 8:100863-100898. https://doi.org/10.18632/oncotarget.19809

Metrics: PDF 1920 views | HTML 5048 views | ?

Abstract

Young Kwang Chae1,2,3, Ayush Arya2, Lauren Chiec2, Hiral Shah1, Ari Rosenberg2, Sandip Patel4, Kirtee Raparia2,3, Jaehyuk Choi2,3, Derek A. Wainwright2,3, Victoria Villaflor1,2,3, Massimo Cristofanilli1,2,3 and Francis Giles1,2,3

1Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA

2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

3Northwestern University Feinberg School of Medicine, Chicago, IL, USA

4University of California San Diego, San Diego, CA, USA

Correspondence to:

Young Kwang Chae, email: [email protected]

Keywords: IHC, FISH, predictive, biomarker, targeted therapy

Received: October 13, 2016 Accepted: April 11, 2017 Published: August 01, 2017

ABSTRACT

Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) and microarray technology. IHC and FISH detection methods for human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug Administration (FDA) as routine clinical practice for cancer patients. Here, we discuss general challenges related to the predictive power of these molecular biomarkers for targeted therapy in cancer medicine. We will also discuss the prospects of utilizing new biomarkers for fibroblast growth factor receptor (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for developing new and robust predictive biomarkers in oncology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19809

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Abstract